These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 19476398)
1. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence? Ziemssen F; Grisanti S; Bartz-Schmidt KU; Spitzer MS Drugs Aging; 2009; 26(4):295-320. PubMed ID: 19476398 [TBL] [Abstract][Full Text] [Related]
2. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Mitchell P Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685 [TBL] [Abstract][Full Text] [Related]
3. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Moja L; Lucenteforte E; Kwag KH; Bertele V; Campomori A; Chakravarthy U; D'Amico R; Dickersin K; Kodjikian L; Lindsley K; Loke Y; Maguire M; Martin DF; Mugelli A; Mühlbauer B; Püntmann I; Reeves B; Rogers C; Schmucker C; Subramanian ML; Virgili G Cochrane Database Syst Rev; 2014 Sep; 9(9):CD011230. PubMed ID: 25220133 [TBL] [Abstract][Full Text] [Related]
4. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Abouammoh M; Sharma S Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks. Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625 [TBL] [Abstract][Full Text] [Related]
6. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? Harvey KJ; Day RO; Campbell WG; Lipworth W Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867 [TBL] [Abstract][Full Text] [Related]
7. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Meyer CH; Holz FG Eye (Lond); 2011 Jun; 25(6):661-72. PubMed ID: 21455242 [TBL] [Abstract][Full Text] [Related]
8. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM; Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163 [TBL] [Abstract][Full Text] [Related]
9. Cancer drug offers effective, cheaper option for AMD. Stephenson J JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231 [No Abstract] [Full Text] [Related]
10. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. van Asten F; Michels CTJ; Hoyng CB; van der Wilt GJ; Klevering BJ; Rovers MM; Grutters JPC PLoS One; 2018; 13(5):e0197670. PubMed ID: 29772018 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Schmucker C; Loke YK; Ehlken C; Agostini HT; Hansen LL; Antes G; Lelgemann M Br J Ophthalmol; 2011 Mar; 95(3):308-17. PubMed ID: 20971791 [TBL] [Abstract][Full Text] [Related]
13. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Abrams P Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC; BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928 [TBL] [Abstract][Full Text] [Related]
15. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN). Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075 [TBL] [Abstract][Full Text] [Related]
16. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration]. Li H; Li X; Xie F Zhonghua Yan Ke Za Zhi; 2014 Jun; 50(6):426-33. PubMed ID: 25241975 [TBL] [Abstract][Full Text] [Related]
17. [Avastin-Lucentis: off-label and surroundings]. Messori A Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536 [TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for neovascular ocular diseases. Lynch SS; Cheng CM Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998 [TBL] [Abstract][Full Text] [Related]
19. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration. Roller AB; Amaro MH Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]